早い Covid-19 実験（する） trialled in care homes
A 早い Covid-19 実験（する） that 約束s results in under an hour is 存在 trialled in care homes.
The 臨床の 裁判，公判, led by Queen Mary University of London, will be carried out in 50 care homes in London with up to 2,000 staff, 訪問者s and 居住（者）s.
The 裁判，公判 目的（とする）s to find out how 効果的な 早い 実験（する）ing is at 減ずるing 率s of 感染, hospitalisation and deaths from coronavirus.
Other 裁判，公判s of 早い 実験（する）s have been 現在進行中の, 含むing one on up to 4,000 people led by Hampshire Hospitals NHS 信用.
For the London 裁判，公判, 居住（者）s, staff and 訪問者s in 25 care homes will be 実験（する）d daily on 早い 実験（する）ing machines, which each have the capacity to 過程 up to 100 見本s a day.
一方／合間, as a comparison, the other 25 care homes will receive the 基準 central 研究室／実験室 実験（する）ing once a week.
Professor Jo ツバメ, from Queen Mary University of London, who is 主要な the 熟考する／考慮する, said: “This work has the 可能性のある to bring a new 早い Covid-19 実験（する）ing system to those at highest 危険, and help interrupt community 伝達／伝染.
“If 設立する to be successful in care homes, it could be very useful in a wide 範囲 of settings, helping to make a quick diagnosis and keep an 環境 解放する／自由な of Covid-19.
“With 早い daily 実験（する）ing, we can 報告（する）／憶測 支援する to the care home on the same day, so that they can take 活動／戦闘 to 減ずる 伝達／伝染 in their care home and 妨げる 突発／発生s into the wider community.
“By 請け負うing this 熟考する／考慮する in the diverse east London community, we’re hoping to 保護する one of the most 攻撃を受けやすい groups in the UK, and the frontline staff who are caring for them.”
The Novacyt Q16 PCR machines used in the 裁判，公判 are designed to be smaller and more 動きやすい than 伝統的な PCR machines, meaning they can be taken to individual 場所／位置s.
